DV
Dividend Vision

MESO — Mesoblast Limited

Mesoblast Limited (MESO)

Total return is 2388.8% over the past 20.6 years, 1604.2 points ahead of SPY at 784.6%. Its deepest 1-year drawdown was 37.1%.

Mesoblast Limited is an individual equity stock in the healthcare sector, an Australia-based regenerative medicine company developing allogeneic cellular therapies for inflammatory and cardiovascular conditions. As a clinical- and early commercial-stage biotechnology company, it does not pay a dividend and reinvests resources into research, development, and commercialization. This international small-cap security suits growth-oriented investors comfortable with the elevated risk profile of biotechnology rather than those seeking dividend income.

MESO key facts

Asset type
Stock
Asset class
Equity
Distribution frequency
None
Last close
$15.60
Market cap
$2,022,610,560
Average volume
164800.0
Beta
0.811
Payout ratio
0.0
Forward P/E
454.5455
EPS
$-0.74